Back to Search
PATRICK FONG, M.D.
M.D.
Internal Medicine Physician
NPI: 1548502131IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
D0100446(MD)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
OTHER
Class of 2013
Research & Publications (20)
Characterization of vectorial chloride transport pathways in the human pancreatic duct adenocarcinoma cell line HPAF.
PMID 12711595·Am J Physiol Cell Physiol·2003
8-other
Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population.
PMID 19367581·Am J Med Genet B Neuropsychiatr Genet·2010
8-other
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
PMID 19608618·Ann Oncol·2010
3-trial
Extending the reverse posterior interosseous artery flap using a de-epithelised bridge segment.
PMID 19251501·J Plast Reconstr Aesthet Surg·2010
5-case
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
PMID 19553641·N Engl J Med·2009
3-trial
A case-crossover study on transient risk factors of work-related eye injuries.
PMID 19286683·Occup Environ Med·2009
4-observational
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
PMID 18695026·Ann Oncol·2009
8-other
Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room.
PMID 19147039·J Am Coll Cardiol·2009
4-observational
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
PMID 19280191·Cancer Chemother Pharmacol·2009
3-trial
Mouse models for human epithelial disease: novel insights and new horizons.
PMID 19144746·Exp Physiol·2009
7-preclinical
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
PMID 19341815·Nanomedicine·2009
7-preclinical
Assessment of QM/MM scoring functions for molecular docking to HIV-1 protease.
PMID 19309119·J Chem Inf Model·2009
8-other
Carbon dioxide laser vaporization of facial siliconomas: flash in the pan or way of the future?
PMID 18443508·Ann Plast Surg·2008
5-case
Norfluoxetine induces spawning and parturition in estuarine and freshwater bivalves.
PMID 18787749·Bull Environ Contam Toxicol·2008
7-preclinical
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
PMID 18927309·Clin Cancer Res·2008
3-trial
Macroalgal bioindicators (growth, tissue N, delta(15)N) detect nutrient enrichment from shrimp farm effluent entering Opunohu Bay, Moorea, French Polynesia.
PMID 18031767·Mar Pollut Bull·2008
7-preclinical
The impacts of human visitation on mussel bed communities along the California coast: are regulatory marine reserves effective in protecting these communities?
PMID 18185953·Environ Manage·2008
7-preclinical
The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance.
PMID 17522594·Clin Pharmacol Ther·2008
2-rct
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
PMID 18000498·Br J Cancer·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 13952 BALTIMORE AVE
LAUREL, MD 20707 - Phone
- (301) 490-1990
Quick Facts
- NPI
- 1548502131
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 13
- Publications
- 20
Are you this provider?
Claim Your Profile